Dear All, A key theme of all discussions on Pull incentives is that substantial rewards should go only to molecules with high medical value. We’re still learning to define the idea of high value and today’s newsletter brings together 3 threads that feed into this conversation: First, we have the idea a priority pathogen list.
Dear All, As you know, WHO updates their preclinical and clinical pipeline summaries at regular intervals. The most current reviews are summarized on https://13.43.35.2/pathogens-and-pipelines/. These excellent summaries are invaluable for researchers of all types and are also used to inform policy work. There is now a call to for current information on antibacterial pre-clinical projects. Go here
Dear All, WHO have now released the first version of an antibiotic handbook based specifically on their AWaRe scheme (Access, Watch, Reserve). Here are the links you need: Press release: https://www.who.int/news/item/09-12-2022-moving-who-guidance-on-antibiotics-into-the-heart-of-clinical-practice Book: https://apps.who.int/iris/handle/10665/365237 Just the infographics from the book: https://apps.who.int/iris/handle/10665/365135 We’ve known this was coming based on the draft EML (Essential Medicines List) Antibiotic handbook
Dear All, Based on a 2020 RFP, we’ve known that WHO was building a fungal priority pathogen list (PPL). Well, now the list has been released. Here’s what you need to understand the new PPL: Webpage where you can get the report My PowerPoint .pptx that summarizes all the PPLs to date My webpage that provides
Dear All, In addition to forming the inaugural WHO Task Force of AMR Survivors, the WHO has also recently released a report entitled “Awareness-raising on Antimicrobial Resistance: Report of global consultation meetings.” The report is based on discussions at two meetings held by WHO with stakeholders from across the world. Even before opening the report,
Dear All, The WHO has announced a call for expressions of interests from AMR survivors and their caregivers to serve in the inaugural WHO Task Force of AMR Survivors! WHO are specifically looking for both (i) survivors of a drug-resistant infection and (ii) anyone who was a direct caregiver of such a patient. Their goal is
See also This related newsletter: 29 Mar 2021, entitled “Vaccines to turn back the tide of antimicrobial resistance.” This 20 Oct 2024 report from WHO: “Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use: technical report” This 25 Apr 2024 paper in Lancet Global Health by Hausdorff and colleagues: “Facilitating the development
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact
Dear All, Continuing on the theme of helping countries develop their own national action plans, WHO released the “WHO implementation handbook for national action plans on antimicrobial resistance: guidance for the human health sector“. The handbook has some great infographics like the one below and will shortly be translated into French, Spanish, and Russian. There
Dear All, I learned today from our colleagues at WHO that Alphafold has recently added the proteome of nearly all the WHO priority pathogens to their library of highly accurate prediction of protein structures. Alphafold was new to me and is amazing! Per our colleagues at WHO: AlphaFold is an AI system developed by DeepMind that